Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anticancer agent 83 是一种强效抗癌剂,抑制 LOX IMVI 细胞生长的 GI50为 0.15 mM。Anticancer agent 83 能够降低线粒体膜电位,并诱导 DNA 损伤,以诱导白血病细胞凋亡 (apoptosis)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 14,900 | 6-8周 | ||
50 mg | ¥ 19,420 | 6-8周 | ||
100 mg | ¥ 24,625 | 6-8周 |
产品描述 | Anticancer Agent 83, a potent inhibitor of LOX IMVI cell growth, demonstrates anticancer efficacy with a GI50 value of 0.15 mM. It disrupts mitochondrial membrane potential and induces DNA damage, thereby promoting apoptosis in leukemia cells [1]. |
体外活性 | Anticancer agent 83 (compound 4a) (0.01-100 μM; 24 h) showing strong activity towards human colon carcinoma HCT116 p53 / cells with deletion of P53 gene (GI 50 =8.4 μM), human epidermoid cervix carcinoma KB3-1 (GI 50 =7.4 μM), human ovarian carcinoma Skov 3 cells (GI 50 =10 μM), and human chronic myelogenous leukemia K562 cells (GI 50 =5.4 μM) [1]. Anticancer agent 83 (0.5 μM; 24 h) interrupts DNA stability and induction of apoptosis in Jurkat cells, and decreases mitochondrial membrane potential [1]. Cell Viability Assay [1] Cell Line: Human colon carcinoma HCT116 p53 / cells with deletion of P53 gene, human epidermoid cervix carcinoma KB3-1, human ovarian carcinoma Skov 3 cells, and human chronic myelogenous leukemia K562 cells Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation Time: 24 hours Result: Inhibited cell viability in different cells with GI 50 s of 8.4 M (HCT116 p53 / ), 7.4 M (KB3-1), 10 M (Skov 3), and 5.4 M (K562), respectively. Immunofluorescence [1] Cell Line: Jurkat cells Concentration: 0.5 μM Incubation Time: 24 hours Result: Induced morphological changes (including apoptotic bodies, membrane blebbing, chromatin condensation), and DNA fragmentation in Jurkat T-cells. |
分子量 | 377.46 |
分子式 | C20H19N5OS |
CAS No. | 904815-29-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Anticancer agent 83 904815-29-8 Inhibitor inhibitor inhibit